Group 1: Investor Relations Activities - The company conducted an earnings briefing on May 20, 2025, via the "Investor Relations Interactive Platform" [3] - Participants included investors attending the online collective reception day for listed companies in Shanxi [3] - Key representatives from the company included General Manager Yan Lingpeng and Secretary of the Board and Financial Officer Yan Xueye [3] Group 2: Market Value Management - The company emphasizes the importance of market value management, with the Board Office as the executing department [5] - It aims to enhance operational efficiency and profitability while maintaining transparent communication with investors [5] - The company is committed to complying with national requirements for market value management to create greater value for shareholders [5] Group 3: Sales Model Distribution - In 2024, direct sales accounted for 50.13% of the business, while distribution accounted for 47.09% [6] - In 2023, direct sales were 41.36%, and distribution was 56.60% [6] - The company aims to develop both sales models simultaneously to promote balanced growth [6] Group 4: Product Applications - Certain single-strain products and enzyme preparations can be used as ingredients in pet food [6] - These products help regulate gut microbiota, improve digestion, and enhance immunity in pets [6] Group 5: Research and Innovation Plans - The company will focus on the development of microbial application technology and core technology self-research [7] - Plans include deepening the "microbial enzyme peptide" technology system and expanding products for poultry and aquaculture [7] - The company aims to improve the antibacterial effects of enzyme preparations and optimize production processes [7]
大禹生物(871970) - 投资者关系活动记录表